VAT Trap Blog

Traditional cardiac risk focused on cholesterol, blood pressure, and smoking. But patients with perfect numbers still had heart attacks. The missing factor was visceral fat creating inflammation that makes arteries vulnerable to damage.

Learn how to measure blood pressure accurately at home using an app to calculate averages, trends, and cardiovascular risk insights.

After 60, muscle becomes deaf to protein signals. You need 3 grams of leucine per meal, not just daily totals, to flip your muscle-building switch. Same protein portions that worked at 40 barely register at 70. Threshold dosing with resistance training breaks this cycle. 44 words · Blog listings · Patient waiting room · Clinic handouts · ADL knowledge chunk

Learn how to measure your waist correctly using anatomical landmarks to better assess visceral fat and cardiometabolic risk.

Visceral fat, strength, and metabolic precision now matter more than weight alone — redefining cardiovascular prevention without defaulting to GLP-1 therapy.

Five key metrics—blood pressure, ApoB, glucose patterns, waist ratio, and muscle strength—redefine cardiovascular risk beyond outdated BMI measurements.

GLP-1 therapies reduce cardiovascular events, likely through visceral adipose tissue reduction, reframing cardiology treatment toward upstream metabolic disease targeting

Visceral fat sits silently behind heart disease, dementia, prediabetes, joint pain and aggressive prostate cancer risk

Fructose quietly drives visceral fat, insulin resistance, and small dense LDL, reshaping cardiovascular risk within today’s ultra-processed food environment modern.

Two patients. Same LDL. One needs a statin. The other needs a tape measure. Here's how to tell which one you are.

Simple grip strength testing predicts heart disease better than blood pressure. Two three-minute muscle function tests reveal your metabolic resilience and can be tracked at home monthly. Strong muscles actively fight visceral fat accumulation across all cardiovascular risk factors.

When a patient arrives breathless and unable to climb a hill, the instinct is to blame the heart. Sometimes the answer lies in the blood itself. Iron deficiency anaemia reduces oxygen delivery, forces the heart into a hyperdynamic state, and can even produce a murmur over a completely normal valve.

In cardiometabolic medicine, muscle is not a cosmetic tissue but a metabolic organ. Evidence consistently shows that strength, not muscle mass, predicts insulin resistance, cardiovascular risk, and survival. Many older adults are not losing muscle tissue — they are losing muscle function, and that is the pathology that matters.

What if the heart works like a hybrid engine? Continuously switching between fatty acids, glucose, and ketones, it optimises fuel use for efficiency and demand. But in metabolic disease, this flexibility is lost. The result: poorer fuel, narrowed supply lines, and a strained engine — a new way to understand cardiovascular risk.

LDL-C alone may miss important cardiovascular risk. This article explains why ApoB and small dense LDL often better reflect atherosclerotic burden, especially in metabolic disease and high visceral fat. It outlines practical lipid targets by risk category and shows how LDL-C:ApoB ratios can estimate dangerous particle patterns

If the pharmacological effects of GLP-1 drugs disappear within weeks, why does the weight rebound take years? And how can that gap be used as a permanent metabolic reset? Written by Dr Edward Leatham, Consultant Cardiologist © 2026 E. Leatham VAT-TRAP Series Key Clinical Findings 1 1 Weight regain is slow despite rapid drug clearance. GLP-1 pharmacological effects fade within weeks, yet full weight rebound takes an average of 1.7 years — because body weight is biologically d

Continuous glucose monitors reveal how differently individuals respond to carbohydrates. We classify these responses using Glucotype, which reflects innate carbohydrate tolerance, and Current Glucose Profile (CGP), which shows a person’s present metabolic state. Combined with visceral fat grading, this system helps identify metabolic risk and guide personalised dietary or medical interventions.

Prediabetes should be viewed as an active cardiometabolic disease stage rather than a passive risk marker. Cardiovascular injury begins before overt diabetes, creating a critical window for intervention. Lifestyle therapy remains fundamental, while agents such as metformin, GLP-1 receptor agonists, dual incretin therapies, and SGLT2 inhibitors may help modify long-term cardiovascular risk.

Measuring your waist isn’t about shape or clothing size. It’s a simple health check that reflects harmful visceral fat around the organs. Measuring the narrowest point can miss risk. For meaningful results, waist must be measured at a fixed anatomical point and tracked consistently over time.

N-of-1 medicine shifts the focus from population averages to personal biology. This blog series explores how individuals can run simple, safe self-experiments — using themselves as the control — to test plausible health hypotheses, track meaningful outcomes, and discover what genuinely improves their own health and wellbeing over time.